Targeting α-reductase for prostate cancer prevention and treatment

Lucas P. Nacusi, Donald J. Tindall

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Testosterone is the most abundant circulating androgen, and can be converted to dihydrotestosterone (DHT), a more potent androgen, by the α-reductase enzymes in target tissues. Current treatments for prostate cancer consist of reducing androgen levels by chemical or surgical castration or pure antiandrogen therapy that directly targets the androgen receptor (AR). Although these therapies reduce tumor burden and AR activity, the cancer inevitably recurs within 18g-30 months. An approach targeting the androgeng-AR axis at different levels could, therefore, improve the efficacy of prostate cancer therapy. Inhibition of α-reductase is one such approach; however, the two largest trials to investigate the use of the α-reductase inhibitors (5ARIs) finasteride and dutasteride in patients with prostate cancer have shown that, although the incidence of cancer was reduced by 5ARI treatment, those cancers that were detected were more aggressive than in patients treated with placebo. Thus, the best practice for using these drugs to prevent and treat prostate cancer remains unclear.

Original languageEnglish (US)
Pages (from-to)378-384
Number of pages7
JournalNature Reviews Urology
Volume8
Issue number7
DOIs
StatePublished - Jul 2011

Fingerprint

Prostatic Neoplasms
Oxidoreductases
Androgen Receptors
Androgens
Finasteride
Therapeutics
Androgen Antagonists
Neoplasms
Dihydrotestosterone
Castration
Tumor Burden
Practice Guidelines
Testosterone
Placebos
Incidence
Enzymes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Urology

Cite this

Targeting α-reductase for prostate cancer prevention and treatment. / Nacusi, Lucas P.; Tindall, Donald J.

In: Nature Reviews Urology, Vol. 8, No. 7, 07.2011, p. 378-384.

Research output: Contribution to journalArticle

Nacusi, Lucas P. ; Tindall, Donald J. / Targeting α-reductase for prostate cancer prevention and treatment. In: Nature Reviews Urology. 2011 ; Vol. 8, No. 7. pp. 378-384.
@article{99c8039f8b9b4fb9ac0bc2bbc4d31482,
title = "Targeting α-reductase for prostate cancer prevention and treatment",
abstract = "Testosterone is the most abundant circulating androgen, and can be converted to dihydrotestosterone (DHT), a more potent androgen, by the α-reductase enzymes in target tissues. Current treatments for prostate cancer consist of reducing androgen levels by chemical or surgical castration or pure antiandrogen therapy that directly targets the androgen receptor (AR). Although these therapies reduce tumor burden and AR activity, the cancer inevitably recurs within 18g-30 months. An approach targeting the androgeng-AR axis at different levels could, therefore, improve the efficacy of prostate cancer therapy. Inhibition of α-reductase is one such approach; however, the two largest trials to investigate the use of the α-reductase inhibitors (5ARIs) finasteride and dutasteride in patients with prostate cancer have shown that, although the incidence of cancer was reduced by 5ARI treatment, those cancers that were detected were more aggressive than in patients treated with placebo. Thus, the best practice for using these drugs to prevent and treat prostate cancer remains unclear.",
author = "Nacusi, {Lucas P.} and Tindall, {Donald J.}",
year = "2011",
month = "7",
doi = "10.1038/nrurol.2011.67",
language = "English (US)",
volume = "8",
pages = "378--384",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Targeting α-reductase for prostate cancer prevention and treatment

AU - Nacusi, Lucas P.

AU - Tindall, Donald J.

PY - 2011/7

Y1 - 2011/7

N2 - Testosterone is the most abundant circulating androgen, and can be converted to dihydrotestosterone (DHT), a more potent androgen, by the α-reductase enzymes in target tissues. Current treatments for prostate cancer consist of reducing androgen levels by chemical or surgical castration or pure antiandrogen therapy that directly targets the androgen receptor (AR). Although these therapies reduce tumor burden and AR activity, the cancer inevitably recurs within 18g-30 months. An approach targeting the androgeng-AR axis at different levels could, therefore, improve the efficacy of prostate cancer therapy. Inhibition of α-reductase is one such approach; however, the two largest trials to investigate the use of the α-reductase inhibitors (5ARIs) finasteride and dutasteride in patients with prostate cancer have shown that, although the incidence of cancer was reduced by 5ARI treatment, those cancers that were detected were more aggressive than in patients treated with placebo. Thus, the best practice for using these drugs to prevent and treat prostate cancer remains unclear.

AB - Testosterone is the most abundant circulating androgen, and can be converted to dihydrotestosterone (DHT), a more potent androgen, by the α-reductase enzymes in target tissues. Current treatments for prostate cancer consist of reducing androgen levels by chemical or surgical castration or pure antiandrogen therapy that directly targets the androgen receptor (AR). Although these therapies reduce tumor burden and AR activity, the cancer inevitably recurs within 18g-30 months. An approach targeting the androgeng-AR axis at different levels could, therefore, improve the efficacy of prostate cancer therapy. Inhibition of α-reductase is one such approach; however, the two largest trials to investigate the use of the α-reductase inhibitors (5ARIs) finasteride and dutasteride in patients with prostate cancer have shown that, although the incidence of cancer was reduced by 5ARI treatment, those cancers that were detected were more aggressive than in patients treated with placebo. Thus, the best practice for using these drugs to prevent and treat prostate cancer remains unclear.

UR - http://www.scopus.com/inward/record.url?scp=79960205353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960205353&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2011.67

DO - 10.1038/nrurol.2011.67

M3 - Article

VL - 8

SP - 378

EP - 384

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 7

ER -